Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › skin melanoma

Skin melanoma

Part of Cancer

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for skin melanoma

32 trials tracked for skin melanoma: 2 in phase 3 or 4.

32Trials tracked
2Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 2 Phase 2 21 Phase 1 2 Other / NA 7
  1. Phase 3 SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer Completed
  2. Phase 3 S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma Completed
  3. Phase 2 Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma Completed
  4. Phase 2 Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma Completed
  5. Phase 2 Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma Completed
  6. Phase 2 Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma Completed
Show 26 more trials
  1. Phase 2 Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma Completed
  2. Phase 2 A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). Completed
  3. Phase 2 Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma Completed
  4. Phase 2 Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery Completed
  5. Phase 2 Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed
  6. Phase 2 Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma Completed
  7. Phase 2 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Completed
  8. Phase 2 Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery Completed
  9. Phase 2 PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma Completed
  10. Phase 2 Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma Completed
  11. Phase 2 Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma Completed
  12. Phase 2 Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma Completed
  13. Phase 2 Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma Completed
  14. Phase 2 Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery Completed
  15. Phase 2 Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma Completed
  16. Phase 2 Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery Completed
  17. Phase 2 Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery Completed
  18. Phase 1 Vaccine Therapy in Treating Patients With Metastatic Melanoma Completed
  19. Phase 1 Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma Completed
  20. N/A Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors Completed
  21. N/A Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo Completed
  22. N/A Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers Completed
  23. N/A AI-based Medical Device Validation for Early Melanoma Detection Completed
  24. N/A Skin Health Online for Melanoma: Better Risk Assessment Completed
  25. N/A Patient-led Surveillance Compared to Clinician-led Surveillance in People Treated for Localised Melanoma. Completed
  26. N/A Using MC1R Genotype to Impact Melanoma Risk Behavior Completed

Showing the 32 most-cited and recently-updated of 32 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Skin melanoma: what the trials found

New evidence includes the implementation of AI-based Computer-Aided Diagnosis (CAD) Software for skin lesion analysis 1.

Treatment with bevacizumab has been evaluated in multiple studies, including a trial reporting a tumor response rate of 23.8% to 33.3% and progression-free survival at 6 months ranging from 32.8% to 56.1% [14, 16].

Aldesleukin was evaluated in several trials; one study showed a significant increase in tumor-antigen-specific immunity in sentinel immunized nodes (SIN) by Elispot assay (p=0.004), while no significant difference was found in peripheral blood mononuclear cells (PBMC) [18, 21, 22].

Interleukin-2 treatment demonstrated a statistically significant improvement in 5-year relapse-free survival (47% vs 38%, p=0.02), though no significant difference was found in 5-year overall survival (56% vs 56%, p=0.49) 3.

The IC-Green KIT was evaluated in a Phase 3 trial 2.

Recent results — preliminary, needs further review

  • ANV419 was evaluated in a Phase 2 study 4.

For the clinician treating this condition

  • Aldesleukin shows significant evidence of inducing tumor-antigen-specific immunity in sentinel immunized nodes [18, 21, 22].
  • Interleukin-2 is associated with improved 5-year relapse-free survival but does not significantly impact 5-year overall survival 3.
  • Bevacizumab has demonstrated measurable tumor response rates and progression-free survival at 6 months in clinical trials [14, 16].

AI synthesis of 4 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review discusses ginsenosides for skin conditions including psoriasis and dermatitis with noted evidence gaps
Drug Pipeline Sys. Review
Narrative review discusses ginsenosides for skin conditions including psoriasis and dermatitis with noted evidence gaps Review of ginsenosides for skin conditions shows weak evidence and low absorption
This narrative review examines the use of ginsenosides for various skin conditions, including psoriasis, dermatitis, photoaging, chronic non…
A review of ginsenosides for skin issues like psoriasis and melanoma found the evidence is insufficient and absorption is low.
Frontiers Apr 24, 2026

Research across Cancer

Related studies from across the Cancer family.

Encorafenib and Binimetinib Combination Therapy for Patients with BRAF Mutated Cutaneous Melanoma
Oncology RCT
Encorafenib and Binimetinib Combination Therapy for Patients with BRAF Mutated Cutaneous Melanoma Trial Shows Encorafenib and Binimetinib for Melanoma Patients
This trial evaluates the safety and efficacy of encorafenib and binimetinib in patients with resected stage IIB/IIC melanoma.
A clinical trial shows that a combination of encorafenib and binimetinib may improve recurrence-free survival for patients with specific mel…
Sep 11, 2026
Objective response rate correlates with overall survival in nivolumab-containing regimens for metastatic melanoma
Oncology Meta-analysis
Objective response rate correlates with overall survival in nivolumab-containing regimens for metastatic melanoma Nivolumab regimens show link between tumor shrinkage and melanoma survival
This meta-analysis of 1865 treatment-naive patients with metastatic melanoma evaluated the association between clinical surrogates and overa…
New data shows that shrinking tumors and staying stable provides a strong link to longer survival for patients with metastatic melanoma.
Sep 9, 2026
Mitophagy acts as a core barrier to effective immunotherapy in melanoma and other skin cancers
Allergy & Immunology Sys. Review
Mitophagy acts as a core barrier to effective immunotherapy in melanoma and other skin cancers Mitophagy acts as a barrier to skin cancer immunotherapy
This narrative review explores how mitophagy functions as a barrier to immunotherapy in melanoma, cutaneous squamous cell carcinoma, and bas…
A cellular process called mitophagy may help skin cancers hide from the immune system, making it harder for certain treatments to work.
Frontiers Sep 8, 2026
PGE2 signaling via EP receptors drives tumor progression and context-dependent neuroinflammation in various diseases
Drug Pipeline Sys. Review
PGE2 signaling via EP receptors drives tumor progression and context-dependent neuroinflammation in various diseases Understanding the Role of PGE2 Signaling in Brain Health and Cancer
This systematic review examines the role of PGE2 signaling across neurological, oncological, and metabolic conditions. The findings indicate…
New research shows how different parts of a single protein pathway can either protect your brain or help tumors grow.
Frontiers Aug 23, 2026
mRNA vaccines offer a flexible and rapid production platform for personalized melanoma immunotherapy
Drug Pipeline Sys. Review
mRNA vaccines offer a flexible and rapid production platform for personalized melanoma immunotherapy mRNA Vaccines Show Promise for Treating Melanoma Cancer
This systematic review examines mRNA cancer vaccines, including lipid nanoparticle delivery systems, as potential treatments for melanoma. T…
New research highlights mRNA technology as a flexible and fast way to develop personalized treatments for melanoma patients.
Frontiers Aug 23, 2026
Fecal microbiota transplantation may modulate tumor microenvironment and enhance immunotherapy responses in several cancers
Oncology Sys. Review
Fecal microbiota transplantation may modulate tumor microenvironment and enhance immunotherapy responses in several cancers Fecal Microbiota Transplantation Shows Potential for Several Cancer Treatments
This systematic review explores the role of fecal microbiota transplantation (FMT) in treating colorectal cancer, liver cancer, and melanoma…
Fecal microbiota transplantation may help manage side effects and improve how the body responds to cancer treatments like chemotherapy and i…
Frontiers Aug 2, 2026
Pregnancy-associated melanoma does not independently worsen overall survival when stage is adequately controlled
Dermatology Meta-analysis
Pregnancy-associated melanoma does not independently worsen overall survival when stage is adequately controlled Pregnancy associated melanoma does not lower overall survival rates
This meta-analysis of observational studies involving 16,467 women found no significant difference in overall survival for patients with pre…
New data shows that a melanoma diagnosis during or shortly after pregnancy does not change the long-term survival outlook for women.
Aug 2, 2026
CD73-adenosine axis serves as a metabolic immune checkpoint and potential target to overcome melanoma resistance
Oncology Sys. Review
CD73-adenosine axis serves as a metabolic immune checkpoint and potential target to overcome melanoma resistance CD73 Target May Help Overcome Melanoma Treatment Resistance
This systematic review examines the role of the CD73-adenosine axis in advanced melanoma and its implications for treatment resistance. The …
New research explores how blocking the CD73-adenosine axis could help patients with advanced melanoma overcome resistance to current treatme…
Frontiers Aug 1, 2026
AI-assisted clinicians achieve 1.000 sensitivity in melanoma diagnosis but autonomous AI lacks clear clinical advantage
Rheumatology Meta-analysis
AI-assisted clinicians achieve 1.000 sensitivity in melanoma diagnosis but autonomous AI lacks clear clinical advantage Artificial Intelligence Shows Mixed Results in Detecting Melanoma
This meta-analysis of 17 diagnostic arms from 10 studies evaluates artificial intelligence for dermoscopic image analysis in melanoma detect…
New research shows that while AI can help identify skin cancer, it does not yet outperform traditional methods used by doctors.
Frontiers Jul 28, 2026
Opsin 3 serves as a potential therapeutic target for melanoma and inflammatory skin diseases
Rheumatology Sys. Review
Opsin 3 serves as a potential therapeutic target for melanoma and inflammatory skin diseases Opsin 3 May Offer New Path for Skin Disease Treatment
This narrative review explores the role of Opsin 3 (OPN3) in skin pathophysiology, including its involvement in UV damage, melanoma developm…
A protein called Opsin 3 may play a key role in how skin cells respond to UV damage, aging, and inflammation.
Frontiers Jul 18, 2026
AI diagnostic tools show high accuracy but limited real-world validation in systematic review
Oncology Meta-analysis
AI diagnostic tools show high accuracy but limited real-world validation in systematic review Artificial intelligence shows high accuracy in detecting various medical conditions
This systematic review of 24 studies synthesizes evidence on AI and deep learning for disease detection across multiple imaging modalities. …
New analysis of 24 studies shows AI tools can reach over 90% accuracy in spotting everything from lung cancer to skin disorders.
Frontiers Jul 18, 2026
Actinic keratosis increases melanoma risk while alcohol consumption is associated with lower squamous cell carcinoma risk
Genetics & Precision Medicine Meta-analysis
Actinic keratosis increases melanoma risk while alcohol consumption is associated with lower squamous cell carcinoma risk Actinic Keratosis Linked to Higher Risk of Melanoma
This meta-analysis of genome-wide association studies evaluates causal relationships between 11 modifiable risk factors and skin cancers. Th…
New research identifies a link between actinic keratosis and melanoma risk while highlighting potential new targets for skin cancer treatmen…
Frontiers Jul 8, 2026